Enaminone-chromone-derivative-CpdC20
AChE inhibition (IC50 = 1.78 microM: MAO-B inhibition (IC50 = 0.06 +/6 0.04 microM
General
Type : Monoamine-oxidase-inhibitor, Multitarget, Chromen
Chemical_Nomenclature : (3Z,3E)-3,3-((1,4-phenylenebis(azanediyl))bis(methaneylylidene))bis(6-hydroxy-2-methoxychroman-4-one)
Canonical SMILES : C1(=CC=C(C=C1)NC=C3\/C(OC2=CC=C(C=C2C3=O)O)OC)NC=C5\/C(C4=CC(=CC=C4OC5OC)O)=O
InChI : InChI=1S\/C28H24N2O8\/c1-35-27-21(25(33)19-11-17(31)7-9-23(19)37-27)13-29-15-3-5-16(6-4-15)30-14-22-26(34)20-12-18(32)8-10-24(20)38-28(22)36-2\/h3-14,27-32H,1-2H3
InChIKey : DTADJGJVXMJLQR-UHFFFAOYSA-N
Other name(s) : Compound C20
Target
References (1)
| Title : Design, synthesis, and multi-target evaluation of Chromone-based derivatives as promising anti-Alzheimer's disease agents - Lu_2025_Bioorg.Chem_168_109350 |
| Author(s) : Lu JH , Zhao CH , Qiu YQ , Shen LQ , Zhang M , Zhu H |
| Ref : Bioorg Chem , 168 :109350 , 2025 |
| Abstract : |
| PubMedSearch : Lu_2025_Bioorg.Chem_168_109350 |
| PubMedID: 41389606 |